Compare FLO & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLO | VCEL |
|---|---|---|
| Founded | 1919 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2000 | 1996 |
| Metric | FLO | VCEL |
|---|---|---|
| Price | $8.54 | $35.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $11.20 | ★ $58.50 |
| AVG Volume (30 Days) | ★ 4.3M | 707.3K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.98% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 0.40 | 0.32 |
| Revenue | ★ $5,256,479,000.00 | $276,259,000.00 |
| Revenue This Year | N/A | $19.10 |
| Revenue Next Year | $0.65 | $17.95 |
| P/E Ratio | ★ $20.66 | $109.84 |
| Revenue Growth | 3.00 | ★ 16.45 |
| 52 Week Low | $7.86 | $28.95 |
| 52 Week High | $18.53 | $45.97 |
| Indicator | FLO | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 58.72 |
| Support Level | N/A | $34.26 |
| Resistance Level | $8.62 | $38.48 |
| Average True Range (ATR) | 0.30 | 1.37 |
| MACD | 0.09 | 0.46 |
| Stochastic Oscillator | 87.58 | 94.67 |
Flowers Foods Inc operates as a producer and marketer of packaged bakery foods in the United States. Its principal products include breads, buns, rolls, snack items (bars, cakes, cookies, and crackers), bagels, English muffins, tortillas, and baking mixes. These products are sold under the brand names Nature's Own, Dave's Killer Bread (DKB), Canyon Bakehouse, Simple Mills, Wonder, and Tastykake. The company derives the majority of its revenue from the sales of its bakery products.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.